Physician profile
Rachel E Ayers
NPI 1265928436
$1,735.83
in general payments reported to CMS, 2019-2025
18 companies · $98.01 in 2025
The $98.01 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $440 · 2023: $251 · 2024: $828 · 2025: $98.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.17 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.94 | 2022-2024 | Entyvio, Gattex, Eohilia |
| Braintree Laboratories, INC. | $112.92 | 2023-2024 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $102.07 | 2024 | Resmetirom |
| Qol Medical, LLC | $78.33 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $77.04 | 2023-2024 | Dupixent |
| Pfizer INC. | $45.64 | 2024 | |
| Janssen Biotech, INC. | $43.25 | 2022-2024 | Stelara |
| Ferring Pharmaceuticals INC. | $39.70 | 2022-2024 | Clenpiq |
| Gilead Sciences, INC. | $38.09 | 2023-2024 | |
| Celgene Corporation | $35.38 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.29 | 2022-2024 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $26.57 | 2024 | Givlaari |
| Ardelyx, INC. | $23.63 | 2024 | Ibsrela |
| Biohaven Pharmaceuticals, INC. | $19.09 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17.76 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $15.94 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $14.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.